Yantai Ruikangda

Yantai Ruikangda Biotechnology is a clinical-stage biopharmaceutical company based in Yantai, China, specializing in the development of innovative cell therapies for cancer. The company focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies to treat hematological malignancies and solid tumors. Its lead programs target well-established antigens such as CD19 and BCMA, with ongoing clinical trials in China. Ruikangda aims to improve the efficacy and safety of cell therapies through its proprietary technology platforms and in-house GMP manufacturing capabilities. The company is positioned as a key innovator within the regional life sciences cluster in Shandong province.